Skip to main content
. Author manuscript; available in PMC: 2015 Sep 10.
Published in final edited form as: Dig Dis Sci. 2014 Feb 7;59(4):886–891. doi: 10.1007/s10620-014-3038-1

Fig. 2.

Fig. 2

Survival over time in end stage liver disease (ESLD) patients with hepatocellular disease. There was a distinct survival advantage for the large LV/IBW group in group 1—patients with hepatocellular injury (X2 = 9.62, p = 0.002)